IDEAS home Printed from https://ideas.repec.org/h/pal/palchp/978-1-349-23423-3_14.html
   My bibliography  Save this book chapter

Japanese Pharmaceutical Firms: Players in the European Market?

In: The Global Competitiveness of the Asian Firm

Author

Listed:
  • Jocelyn Probert

Abstract

The pharmaceuticals sector ranks among the very few segments of Japanese industry that has yet to make a major mark on the international scene. Competitive advantages which other industries in Japan, such as cars and consumer electronics, have successfully exploited — namely incremental advances in development and production technology, productivity, low-cost manufacturing — are rather less relevant to the development of the pharmaceutical industry. The very structure of the industry mitigates against such competitive advantages: producer firms supply customers but are paid by a third party (the government), creating an insensitivity to price in the demand for drugs which, in turn, all but eliminates corporate considerations of cost and productivity.

Suggested Citation

  • Jocelyn Probert, 1994. "Japanese Pharmaceutical Firms: Players in the European Market?," Palgrave Macmillan Books, in: Hellmut Schütte (ed.), The Global Competitiveness of the Asian Firm, chapter 14, pages 232-264, Palgrave Macmillan.
    • Handle: RePEc:pal:palchp:978-1-349-23423-3_14
    DOI: 10.1007/978-1-349-23423-3_14
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ramani, Shyama V., 2002. "Who is interested in biotech? R&D strategies, knowledge base and market sales of Indian biopharmaceutical firms," Research Policy, Elsevier, vol. 31(3), pages 381-398, March.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:pal:palchp:978-1-349-23423-3_14. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.palgrave.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.